LV11906B - NEW BODY ORGANISMS WITH SPECIFIC RELATED PEPTITIS COUPLING - Google Patents
NEW BODY ORGANISMS WITH SPECIFIC RELATED PEPTITIS COUPLING Download PDFInfo
- Publication number
- LV11906B LV11906B LVP-97-04A LV970004A LV11906B LV 11906 B LV11906 B LV 11906B LV 970004 A LV970004 A LV 970004A LV 11906 B LV11906 B LV 11906B
- Authority
- LV
- Latvia
- Prior art keywords
- peptide
- host cell
- modified host
- protein
- receptor
- Prior art date
Links
- 230000008878 coupling Effects 0.000 title 1
- 238000010168 coupling process Methods 0.000 title 1
- 238000005859 coupling reaction Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 263
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 212
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 136
- 230000027455 binding Effects 0.000 claims abstract description 128
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 58
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 56
- 230000004568 DNA-binding Effects 0.000 claims abstract description 45
- 238000012360 testing method Methods 0.000 claims abstract description 17
- 230000035772 mutation Effects 0.000 claims abstract description 11
- 238000012217 deletion Methods 0.000 claims abstract description 9
- 230000037430 deletion Effects 0.000 claims abstract description 9
- 239000013611 chromosomal DNA Substances 0.000 claims abstract description 8
- 102000005962 receptors Human genes 0.000 claims description 122
- 108020003175 receptors Proteins 0.000 claims description 122
- 239000003446 ligand Substances 0.000 claims description 82
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 230000003993 interaction Effects 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 41
- 108010051696 Growth Hormone Proteins 0.000 claims description 39
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 39
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 39
- 239000000122 growth hormone Substances 0.000 claims description 39
- 230000004913 activation Effects 0.000 claims description 34
- 239000013612 plasmid Substances 0.000 claims description 32
- 102100038803 Somatotropin Human genes 0.000 claims description 31
- 102100039556 Galectin-4 Human genes 0.000 claims description 21
- 239000002299 complementary DNA Substances 0.000 claims description 21
- 108010057464 Prolactin Proteins 0.000 claims description 20
- 102100024819 Prolactin Human genes 0.000 claims description 19
- 229940097325 prolactin Drugs 0.000 claims description 18
- 239000006152 selective media Substances 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 14
- 230000035897 transcription Effects 0.000 claims description 14
- 239000003102 growth factor Substances 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 108010058643 Fungal Proteins Proteins 0.000 claims description 7
- 230000002538 fungal effect Effects 0.000 claims description 7
- 239000000813 peptide hormone Substances 0.000 claims description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 6
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 6
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 6
- 229940040129 luteinizing hormone Drugs 0.000 claims description 6
- 108020004635 Complementary DNA Proteins 0.000 claims description 5
- 238000010804 cDNA synthesis Methods 0.000 claims description 5
- 108010045747 interleukin 3 receptor-like molecule Proteins 0.000 claims description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 4
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 108020004017 nuclear receptors Proteins 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 3
- 108090000394 Erythropoietin Proteins 0.000 claims description 3
- 101000799969 Escherichia coli (strain K12) Alpha-2-macroglobulin Proteins 0.000 claims description 3
- 108010087819 Fc receptors Proteins 0.000 claims description 3
- 102000009109 Fc receptors Human genes 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102100037362 Fibronectin Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 108060003199 Glucagon Proteins 0.000 claims description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 3
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 108090001007 Interleukin-8 Proteins 0.000 claims description 3
- 102000004890 Interleukin-8 Human genes 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 108060001084 Luciferase Proteins 0.000 claims description 3
- 102000004140 Oncostatin M Human genes 0.000 claims description 3
- 108090000630 Oncostatin M Proteins 0.000 claims description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 3
- 101150005828 SWI5 gene Proteins 0.000 claims description 3
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims description 3
- 102100037505 Secretin Human genes 0.000 claims description 3
- 108010086019 Secretin Proteins 0.000 claims description 3
- 102000003800 Selectins Human genes 0.000 claims description 3
- 108090000184 Selectins Proteins 0.000 claims description 3
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 3
- 102000011923 Thyrotropin Human genes 0.000 claims description 3
- 108010061174 Thyrotropin Proteins 0.000 claims description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 229940105423 erythropoietin Drugs 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 229960004666 glucagon Drugs 0.000 claims description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 229940047124 interferons Drugs 0.000 claims description 3
- 229940096397 interleukin-8 Drugs 0.000 claims description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 101150066555 lacZ gene Proteins 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002101 secretin Drugs 0.000 claims description 3
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229960000874 thyrotropin Drugs 0.000 claims description 3
- 230000001748 thyrotropin Effects 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 230000002227 vasoactive effect Effects 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 68
- 210000005253 yeast cell Anatomy 0.000 claims 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 101150111329 ACE-1 gene Proteins 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 101100490563 Caenorhabditis elegans adr-1 gene Proteins 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 108010078321 Guanylate Cyclase Proteins 0.000 claims 1
- 102000014469 Guanylate cyclase Human genes 0.000 claims 1
- 101150009243 HAP1 gene Proteins 0.000 claims 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 108010003044 Placental Lactogen Proteins 0.000 claims 1
- 239000000381 Placental Lactogen Substances 0.000 claims 1
- 102000015215 Stem Cell Factor Human genes 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 101150020580 yap1 gene Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 abstract description 51
- 102000037865 fusion proteins Human genes 0.000 abstract description 51
- 238000012216 screening Methods 0.000 abstract description 11
- 230000004927 fusion Effects 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 32
- 102100020948 Growth hormone receptor Human genes 0.000 description 28
- 108010068542 Somatotropin Receptors Proteins 0.000 description 27
- 230000000875 corresponding effect Effects 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 20
- 108010002519 Prolactin Receptors Proteins 0.000 description 19
- 230000008859 change Effects 0.000 description 17
- 239000013598 vector Substances 0.000 description 16
- 108010001515 Galectin 4 Proteins 0.000 description 15
- 102100029000 Prolactin receptor Human genes 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 238000006471 dimerization reaction Methods 0.000 description 9
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 101100250396 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL28 gene Proteins 0.000 description 6
- 101100527649 Wickerhamomyces ciferrii (strain ATCC 14091 / BCRC 22168 / CBS 111 / JCM 3599 / NBRC 0793 / NRRL Y-1031 F-60-10) RPL44 gene Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 101150009006 HIS3 gene Proteins 0.000 description 4
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 4
- 102000023732 binding proteins Human genes 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 230000010799 Receptor Interactions Effects 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 102000017178 Guanylate Cyclase-Coupled Receptors Human genes 0.000 description 2
- 108010013990 Guanylate Cyclase-Coupled Receptors Proteins 0.000 description 2
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 2
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 2
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 101000687489 Sus scrofa Prolactin Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000002805 secondary assay Methods 0.000 description 2
- 108010050014 systemin Proteins 0.000 description 2
- HOWHQWFXSLOJEF-MGZLOUMQSA-N systemin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]2N(CCC2)C(=O)[C@H]2N(CCC2)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)CCC1 HOWHQWFXSLOJEF-MGZLOUMQSA-N 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 101150008604 CAN1 gene Proteins 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 101000620967 Diplobatis ommata Ras-related protein Rab-11B Proteins 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100409239 Mus musculus Prlr gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101100448397 Rattus norvegicus Ghr gene Proteins 0.000 description 1
- 101001075257 Rattus norvegicus Growth hormone receptor Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 101100441839 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOF1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108010066540 copper thionein Proteins 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 108010005905 delta-hGHR Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 230000008606 intracellular interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 101150047627 pgk gene Proteins 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 108010033419 somatotropin-binding protein Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/259,609 US5989808A (en) | 1994-06-14 | 1994-06-14 | Identification of compounds affecting specific interaction of peptide binding pairs |
| PCT/US1995/006895 WO1995034646A1 (en) | 1994-06-14 | 1995-05-31 | Novel cell systems having specific interaction of peptide binding pairs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV11906A LV11906A (lv) | 1997-12-20 |
| LV11906B true LV11906B (en) | 1998-06-20 |
Family
ID=22985626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-97-04A LV11906B (en) | 1994-06-14 | 1997-02-14 | NEW BODY ORGANISMS WITH SPECIFIC RELATED PEPTITIS COUPLING |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US5989808A (de) |
| EP (1) | EP0765389B1 (de) |
| AT (1) | ATE245189T1 (de) |
| AU (1) | AU706173B2 (de) |
| CA (1) | CA2195083A1 (de) |
| DE (1) | DE69531302T2 (de) |
| DK (1) | DK0765389T3 (de) |
| ES (1) | ES2202366T3 (de) |
| GE (1) | GEP20022619B (de) |
| IL (1) | IL114118A0 (de) |
| LT (1) | LT4230B (de) |
| LV (1) | LV11906B (de) |
| NZ (1) | NZ287372A (de) |
| PT (1) | PT765389E (de) |
| RU (1) | RU2208646C2 (de) |
| SI (1) | SI9520073B (de) |
| WO (1) | WO1995034646A1 (de) |
| ZA (1) | ZA954892B (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7226761B2 (en) * | 1992-11-05 | 2007-06-05 | Danisco Sweeteners Oy | Manufacture of five-carbon sugars and sugar alcohols |
| US6972193B1 (en) * | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| US6891021B2 (en) | 1993-02-12 | 2005-05-10 | Board Of Trustees Of The Leland Stanford Junior University | Regulated apoptosis |
| US6770446B1 (en) * | 1994-06-14 | 2004-08-03 | Wyeth | Cell systems having specific interaction of peptide binding pairs |
| US5610015A (en) * | 1995-03-23 | 1997-03-11 | Wisconsin Alumni Research Foundation | System to detect protein-RNA interactions |
| NZ306767A (en) * | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| US6171800B1 (en) | 1995-06-07 | 2001-01-09 | Biogen, Inc. | Method of making and binding CAIP polypeptides |
| US5837844A (en) * | 1995-06-07 | 1998-11-17 | Biogen, Inc. | CAIP-like gene family |
| US6423824B1 (en) | 1995-06-07 | 2002-07-23 | Biogen, Inc. | CAIP-like gene family |
| EP1241265A3 (de) * | 1996-04-26 | 2004-02-18 | Massachusetts Institute Of Technology | Screening-Verfahren für kleine Liganden |
| DE69715621T2 (de) * | 1996-04-26 | 2003-05-22 | Massachusetts Institute Of Technology, Cambridge | Drei hybriden screening test |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| AU6342696A (en) * | 1996-06-27 | 1998-01-14 | Biogen, Inc. | The caip-like gene family |
| FR2761697B1 (fr) * | 1997-04-03 | 1999-05-28 | Inst Nat Sante Rech Med | Methodes de detection d'interactions entre plusieurs proteines |
| DE19715683C2 (de) * | 1997-04-15 | 1999-11-11 | Max Planck Gesellschaft | Neue Reportervektoren für One-Hybrid und Two-Hybrid Systeme |
| US6787319B2 (en) | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
| US7005295B1 (en) | 1997-04-16 | 2006-02-28 | Wyeth | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
| AU6969998A (en) | 1997-04-25 | 1998-11-24 | American Home Products Corporation | Neuronal mort1 isoforms |
| US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
| JP4296608B2 (ja) * | 1997-08-27 | 2009-07-15 | 田辺三菱製薬株式会社 | Ｐｐａｒのアゴニスト及びアンタゴニストのスクリーニング方法 |
| EP1149920A1 (de) * | 1997-10-15 | 2001-10-31 | Diversa, Inc. | Screening fÜr neue Verbindungen, die biologische Interaktionen regulieren |
| AU1094699A (en) | 1997-10-15 | 1999-05-03 | Diversa Corporation | Screening for novel compounds which regulate biological interactions |
| US6261842B1 (en) | 1997-10-23 | 2001-07-17 | Wisconsin Alumni Research Foundation | Microorganism genomics, compositions and methods related thereto |
| WO1999025739A1 (en) * | 1997-11-14 | 1999-05-27 | Roche Diagnostics Corporation | Variable region fusion peptides that form effector complexes in the presence of antigen |
| CA2317816C (en) | 1998-01-09 | 2009-02-17 | Tvw Telethon Institute For Child Health Research | Peptide detection method |
| EP0974649A1 (de) * | 1998-06-22 | 2000-01-26 | Universität Zürich | Screening-System |
| US7166475B2 (en) | 1999-02-26 | 2007-01-23 | Cyclacel Ltd. | Compositions and methods for monitoring the modification state of a pair of polypeptides |
| GB9907687D0 (en) * | 1999-04-01 | 1999-05-26 | Kudos Pharm Ltd | Assays methods and means |
| WO2000063667A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods for identifying modulators of n-type ion channel inactivation |
| MXPA02010446A (es) * | 2000-04-24 | 2003-04-25 | Wyeth Corp | Sistemas celulares novedosos, con interaccion especifica de los pares que se unen a los peptidos. |
| EP1349946B1 (de) | 2000-08-25 | 2011-01-26 | BASF Plant Science GmbH | Polynukleotide, die für prenylproteasen aus pflanzen kodieren |
| US20020165149A1 (en) * | 2000-12-08 | 2002-11-07 | Kranz David M. | Mutated class II major histocompatibility proteins |
| PT2163614T (pt) | 2002-08-21 | 2017-01-17 | Revivicor Inc | Animais porcinos que carecem de qualquer expressão de alfa 1,3 galactosiltransferase funcional |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| US20070298414A1 (en) * | 2003-11-17 | 2007-12-27 | Doyle Donald F | Engineering Enzymes Through Genetic Selection |
| EP1544307A1 (de) * | 2003-12-18 | 2005-06-22 | AXXAM S.r.l. | Chimärer LAC9 Rezeptor und dessen Verwendungen |
| EP2412816B1 (de) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Verfahren zur verbesserten Proteinexpression durch Strain-Engineering |
| WO2007035213A2 (en) | 2005-08-09 | 2007-03-29 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
| AU2007212390A1 (en) * | 2006-02-07 | 2007-08-16 | Wyeth | Materials and methods for identifying agents that modulate Norrin, Norrin mimetics, and agents identified thereby |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| EP2142651B1 (de) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Schnellscreeningverfahren für bakterienwirte zur identifizierung bestimmter stämme mit verbessertem ertrag und/oder verbesserter qualität bei der expression heterologer proteine |
| CN101131363B (zh) * | 2007-09-30 | 2010-12-01 | 南京大学 | 一种基于酵母三杂交的小分子化合物检测方法 |
| WO2016154452A2 (en) | 2015-03-24 | 2016-09-29 | Osiris Therapeutics, Inc. | Compositions comprising meniscal tissues and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5322801A (en) * | 1990-04-19 | 1994-06-21 | The General Hospital Corporation | Protein partner screening assays and uses thereof |
| ATE256738T1 (de) * | 1992-10-30 | 2004-01-15 | Gen Hospital Corp | Ein neues zellzyklus kontrollprotein |
| US5512473A (en) * | 1993-01-29 | 1996-04-30 | Brent; Roger | Max-interacting proteins and related molecules and methods |
| US5582995A (en) * | 1993-06-11 | 1996-12-10 | The General Hospital Corporation | Methods of screening for compounds which inhibit the direct binding of Ras to Raf |
| CA2180271A1 (en) * | 1993-12-30 | 1995-07-06 | Ronald M. Evans | Novel uses for gal4-receptor constructs |
| US5846764A (en) * | 1994-01-21 | 1998-12-08 | Icos Corporation | Materials and methods relating to proteins that interact with casein kinase I |
| US5525490A (en) * | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5691147A (en) * | 1994-06-02 | 1997-11-25 | Mitotix, Inc. | CDK4 binding assay |
-
1994
- 1994-06-14 US US08/259,609 patent/US5989808A/en not_active Expired - Fee Related
-
1995
- 1995-05-31 EP EP95920689A patent/EP0765389B1/de not_active Expired - Lifetime
- 1995-05-31 AT AT95920689T patent/ATE245189T1/de not_active IP Right Cessation
- 1995-05-31 RU RU97100776/13A patent/RU2208646C2/ru not_active IP Right Cessation
- 1995-05-31 ES ES95920689T patent/ES2202366T3/es not_active Expired - Lifetime
- 1995-05-31 CA CA002195083A patent/CA2195083A1/en not_active Abandoned
- 1995-05-31 NZ NZ287372A patent/NZ287372A/en not_active IP Right Cessation
- 1995-05-31 AU AU26066/95A patent/AU706173B2/en not_active Ceased
- 1995-05-31 SI SI9520073A patent/SI9520073B/sl not_active IP Right Cessation
- 1995-05-31 PT PT95920689T patent/PT765389E/pt unknown
- 1995-05-31 GE GEAP19953531A patent/GEP20022619B/en unknown
- 1995-05-31 DK DK95920689T patent/DK0765389T3/da active
- 1995-05-31 WO PCT/US1995/006895 patent/WO1995034646A1/en active IP Right Grant
- 1995-05-31 DE DE69531302T patent/DE69531302T2/de not_active Expired - Lifetime
- 1995-06-12 IL IL11411895A patent/IL114118A0/xx not_active IP Right Cessation
- 1995-06-13 ZA ZA954892A patent/ZA954892B/xx unknown
-
1997
- 1997-01-13 LT LT97-004A patent/LT4230B/lt not_active IP Right Cessation
- 1997-02-14 LV LVP-97-04A patent/LV11906B/en unknown
-
1999
- 1999-03-08 US US09/263,944 patent/US6251602B1/en not_active Expired - Fee Related
- 1999-05-06 US US09/305,483 patent/US6284519B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA954892B (en) | 1996-01-30 |
| DE69531302D1 (de) | 2003-08-21 |
| ES2202366T3 (es) | 2004-04-01 |
| ATE245189T1 (de) | 2003-08-15 |
| EP0765389A1 (de) | 1997-04-02 |
| EP0765389B1 (de) | 2003-07-16 |
| IL114118A0 (en) | 1995-10-31 |
| DK0765389T3 (da) | 2003-10-27 |
| SI9520073A (sl) | 1998-02-28 |
| US6284519B1 (en) | 2001-09-04 |
| GEP20022619B (en) | 2002-01-25 |
| DE69531302T2 (de) | 2004-04-22 |
| LT4230B (en) | 1997-10-27 |
| US5989808A (en) | 1999-11-23 |
| RU2208646C2 (ru) | 2003-07-20 |
| LV11906A (lv) | 1997-12-20 |
| NZ287372A (en) | 1997-11-24 |
| LT97004A (en) | 1997-07-25 |
| SI9520073B (sl) | 2004-06-30 |
| PT765389E (pt) | 2003-11-28 |
| AU706173B2 (en) | 1999-06-10 |
| WO1995034646A1 (en) | 1995-12-21 |
| CA2195083A1 (en) | 1995-12-21 |
| AU2606695A (en) | 1996-01-05 |
| US6251602B1 (en) | 2001-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0765389B1 (de) | Zellsystem mit einer spezifischen wechselwirkung von peptid-bindenden paaren | |
| Young | Yeast two-hybrid: so many interactions,(in) so little time… | |
| Starr et al. | Intracellular receptors use a common mechanism to interpret signaling information at response elements. | |
| Galsgaard et al. | Identification of a growth hormone-responsive STAT5-binding element in the rat insulin 1 gene. | |
| INOUYE et al. | Isolation of a cDNA encoding a metal response element binding protein using a novel expression cloning procedure: the one hybrid system | |
| US5217867A (en) | Receptors: their identification, characterization, preparation and use | |
| Lee et al. | Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. | |
| Seol et al. | Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. | |
| Bergers et al. | Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron | |
| Miesfeld | The Structure and Function of Steroid Receptor Protein | |
| Lemon et al. | Selective effects of ligands on vitamin D3 receptor-and retinoid X receptor-mediated gene activation in vivo | |
| Le Douarin et al. | A new version of the two-hybrid assay for detection of protein-protein interactions. | |
| Ozenberger et al. | Functional interaction of ligands and receptors of the hematopoietic superfamily in yeast. | |
| EP0907886A1 (de) | Retinoid-x-rezeptoren und komponenten für die grundlegende transkriptions-machinerie | |
| Ponticelli et al. | The glutamine-rich activation domains of human Sp1 do not stimulate transcription in Saccharomyces cerevisiae | |
| AU637446B2 (en) | Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors | |
| US6673540B1 (en) | Cell systems having specific interaction of peptide binding pairs | |
| EP1283870A1 (de) | Neuartiges zellsystem mit spezifischer interaktion von peptidbindungspaaren | |
| Yamaguchi et al. | Functional analysis of aryl hydrocarbon receptor nuclear translocator interactions with aryl hydrocarbon receptor in the yeast two-hybrid system | |
| Huang et al. | cDNA library screening using the SOS recruitment system | |
| JP2002522031A (ja) | 真核細胞ベースの遺伝子相互作用クローニング | |
| Berghöfer‐Hochheimer et al. | Expression of the vitamin D and the retinoid X receptors in Saccharomyces cerevisiae: Alternative in vivo models for ligand‐induced transactivation | |
| Ozenberger et al. | Investigation of Ligand/Receptor Interactions and the Formation of Tertiary Complexes | |
| PAUSCH et al. | HETEROLOGOUS G PROTEIN-COUPLED RECEPTORS EXPRESSED IN SACCHAROMYCES CEREVISIAE: METHODS FOR GENETIC ANALYSIS AND | |
| Cormack | The TATA-binding protein: a mutational analysis |